Meta-Analysis
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Meta-Anal. Feb 28, 2020; 8(1): 27-40
Published online Feb 28, 2020. doi: 10.13105/wjma.v8.i1.27
Long-term efficacy of capecitabine plus oxaliplatin chemotherapy on stage III colon cancer: A meta-analysis
Hong-Tao Fu, Ying-Ying Xu, Jing-Jing Tian, Jia-Xin Fu, Shao-Ling Nie, Yan-Yan Tang, Ping Chen, Liang Zong
Hong-Tao Fu, Department of Clinical Medicine, University of South China, Hengyang 421000, Hunan Province, China
Ying-Ying Xu, Department of General Surgery, Yizheng People’s Hospital, Yangzhou University, Yangzhou 225000, Jiangsu Province, China
Jing-Jing Tian, Department of Laboratory Medicine, The Second Xiangya Hospital, Central South University, Changsha 410013, Hunan Province, China
Jia-Xin Fu, Ping Chen, Liang Zong, Department of General Surgery, Northern Jiangsu People’s Hospital, Yangzhou University, Yangzhou 225000, Jiangsu Province, China
Shao-Ling Nie, Yan-Yan Tang, Department of Colorectal Surgery, Hunan Cancer Hospital, Central South University, Changsha 410000, Hunan Province, China
Author contributions: Fu HT, Xu YY, Tian JJ and Fu JX contributed equally to this work; Zong L and Nie SL were responsible for the conception and design of the study; Fu HT, Tian JJ, Xu YY and Fu JX collected the data and organized data extraction sheets; Fu HT and Tian JJ statistically analyzed the data; Fu HT drafted the manuscript, with critical revision being performed by Zong L and Nie SL.
Conflict-of-interest statement: The authors have no conflicts of interest for this manuscript.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Liang Zong, PhD, Doctor, Professor, Department of General Surgery, Northern Jiangsu People’s Hospital, Yangzhou University, Yangzhou 225000, Jiangsu Province, China. 250537471@qq.com
Received: June 22, 2019
Peer-review started: June 24, 2019
First decision: August 27, 2019
Revised: September 26, 2019
Accepted: October 20, 2019
Article in press: October 20, 2019
Published online: February 28, 2020
Core Tip

Core tip: Many clinical studies for the long-term survival of patients or the efficacy of capecitabine plus oxaliplatin (XELOX) in colon cancer have already been studied, but its clinical benefit is controversial. The long-term efficacy of the XELOX regimen in comparison with other adjuvant chemotherapy protocols in colon cancer was evaluated. By searching the PubMed, EMBASE and Cochrane databases, a total of 12 randomized controlled trials involving 6698 stage III colon cancer cases were included. Our findings showed that XELOX regimen had a better overall survival and a better disease-free survival. The XELOX regimen can be a preferred option for adjuvant treatment of stage III colon cancer after surgery.